Showing 61 - 80 results of 38,220 for search '(( significant burden case ) OR ( significant ((we decrease) OR (teer decrease)) ))', query time: 0.50s Refine Results
  1. 61
  2. 62
  3. 63
  4. 64
  5. 65
  6. 66
  7. 67
  8. 68
  9. 69
  10. 70
  11. 71
  12. 72

    Table_1_Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2− Breast Cancer Patient With High Tumor Mutational Burden.xlsx by Rong Wang (59795)

    Published 2021
    “…Here we present a case of an ER+/HER2- but TMB-high mBC patient who had significant response to combination therapy with anti-PD-1 antibody camrelizumab and vinorelbine and obtained partial response (PR) with a progression-free survival (PFS) of 5 months after failure of multiple lines of therapy. …”
  13. 73
  14. 74
  15. 75
  16. 76
  17. 77
  18. 78
  19. 79
  20. 80